ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1911

Using the Technology Acceptance Model to Assess Physician Perceptions and Experiences Using the Rheumatoid Arthritis-Patient-Reported Outcomes Dashboard: Mixed-Methods Study

Catherine Nasrallah1, Cherish Wilson2, Alicia Hamblin1, Lindsay Jacobsohn1, Cammie Young3, Cammie Young3, Mary Nakamura4, Andrew Gross1, Judith Ashouri1, Mehrdad Matloubian1, Jinoos Yazdany1 and Gabriela Schmajuk2, 1University of California San Francisco, San Francisco, CA, 2UCSF / SFVA, San Francisco, CA, 3University of California San Francisco, Oakland, CA, 4UCSF/SFVAHCS, San Francisco, CA

Meeting: ACR Convergence 2023

Keywords: informatics, Patient reported outcomes, Qualitative Research, quality of care, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1895–1912) Measures & Measurement of Healthcare Quality Poster II

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Improving shared decision-making using a treat-to-target approach, including the use of patient reported outcomes (PROs), is important to providing high quality care for rheumatoid arthritis (RA). We developed an EHR-integrated, patient-facing sidecar dashboard application that displays RA outcomes (disease activity (DA), functional status, pain scores), medications, and lab results for use during clinical visits (Figure 1). The purpose of this study was to assess physician perceptions and experiences using the dashboard in a university rheumatology clinic.

Methods: Data derived from focus group (FG) discussions and surveys with physicians who had access to the dashboard as part of a randomized, stepped-wedge pragmatic trial. FGs explored physician perceptions towards the usability, acceptability, and usefulness of the dashboard. FG data were analyzed thematically using deductive and inductive techniques; emerging themes were categorized according to the Technology Acceptance Model (TAM; Figure 2). Surveys, which were collected during consecutive visits in which the dashboard was not discussed with the patient, queried physicians’ reasons for non-use. Survey data were summarized as proportions.

Results: 3 FGs included 12 rheumatologists and 102 surveys were collected from 14 physicians. Major themes that emerged from the FG analysis as barriers to using the dashboard included inconsistent collection of RA outcomes leading to sparse data in the dashboard and concerns about explaining RA outcomes, especially to patients with fibromyalgia (Table). Other challenges included time constraints and technical difficulties refreshing the dashboard to display real-time data. Nevertheless, physicians were enthusiastic about the dashboard and expressed the usefulness of visualizing RA outcome trajectories in a graphical format for motivating patients, enhancing patient understanding of their RA outcomes, and improving communication about medications. Methods for integrating the dashboard into the visit varied: some physicians used the dashboard at the beginning of the visit as they documented RA outcomes; others used it at the end to justify changes to therapy; and a few shared it only with stable patients. Survey results aligned with the themes identified in the FGs: the most reported reason for not using the dashboard was an assumption that the dashboard would not be useful for the patient (32%) (often because of low DA or comorbid conditions). Other reasons included forgetting to use the dashboard (19%), lack of patient data in the dashboard (12%), and time constraints (12%). Technical difficulties accounted for a small amount of non-use (6%).

Conclusion: We used a mixed-methods approach to assess physician perceptions of a novel EHR sidecar dashboard application that aims to improve the quality of care for RA patients. Despite enthusiasm for the value of this new technology, discomfort with discussing RA outcomes, inconsistent workflows for incorporating the dashboard into the visit, and incomplete EHR data were major reasons for not using the dashboard. Future work should address these barriers to improve uptake of the dashboard.

Supporting image 1

Figure 1: Screenshot of the Rheumatoid Arthritis-Patient-Reported Outcomes Dashboard (RA-PRO)

Supporting image 2

Figure 2: Physician Technology Acceptance Model (TAM) of the RA-PRO dashboard.

Supporting image 3

Table: Physician Perceptions of the RA-PRO dashboard sidecar application: Qualitative Results


Disclosures: C. Nasrallah: None; C. Wilson: None; A. Hamblin: None; L. Jacobsohn: None; C. Young: None; C. Young: None; M. Nakamura: None; A. Gross: None; J. Ashouri: None; M. Matloubian: None; J. Yazdany: Astra Zeneca, 2, 5, Aurinia, 5, Gilead, 5, Pfizer, 2; G. Schmajuk: None.

To cite this abstract in AMA style:

Nasrallah C, Wilson C, Hamblin A, Jacobsohn L, Young C, Young C, Nakamura M, Gross A, Ashouri J, Matloubian M, Yazdany J, Schmajuk G. Using the Technology Acceptance Model to Assess Physician Perceptions and Experiences Using the Rheumatoid Arthritis-Patient-Reported Outcomes Dashboard: Mixed-Methods Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/using-the-technology-acceptance-model-to-assess-physician-perceptions-and-experiences-using-the-rheumatoid-arthritis-patient-reported-outcomes-dashboard-mixed-methods-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/using-the-technology-acceptance-model-to-assess-physician-perceptions-and-experiences-using-the-rheumatoid-arthritis-patient-reported-outcomes-dashboard-mixed-methods-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology